This preprint is under consideration at Journal of Cancer Research and Clinical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Zhizhuo Huang
Peking University People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4376-5399
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose: To assess the prognostic effect of different levels of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Methods: IKZF1 Δ2-8/ALB deletions were quantified using multiplex real-time quantitative PCR in newly diagnosed pediatric BCP-ALL patients. Seventy-four patients with IKZF1 deletions ≥ 0.01% were included. Clinical characteristics, laboratory data, and treatment outcomes were analysed.
Results: The patients were divided into two groups: IKZF1 deletions < 1% (group A) and ≥ 1% (group B). Group B patients had a higher BCR-ABL1 positive rate than did group A patients. The proportions of patients who had an age at onset ≥10 years old, and white blood cell count ≥ 50×109/L were significantly higher in group B than in group A. The 3-year overall survival (OS) and 3-year event-free survival (EFS) rates in group B were 79 ± 8.8% and 62.4 ± 9.7%, respectively, being significantly lower than those in group A (97.7 ± 2.2% and 83.2 ± 5.8%, respectively). The level of IKZF1 deletions ≥ 1% and the central nervous system leukemia were independent risk factors of EFS.
Conclusions: Pediatric BCP-ALL patients with high levels of IKZF1 gene deletions have a poorer prognosis than those with low levels.
Keywords
children, acute lymphoblastic leukemia, IKZF1 gene deletion, quantitative, clinical characteristics, prognosis
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 Mar, 2021
No community comments so far
Reviewers invited
Invitations sent on 16 Mar, 2021
Editor invited
On 16 Mar, 2021
Review #? received
Received 16 Mar, 2021
First submitted
On 11 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Journal of Cancer Research and Clinical Oncology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Zhizhuo Huang
Peking University People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4376-5399
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 19 Mar, 2021
No community comments so far
Reviewers invited
Invitations sent on 16 Mar, 2021
Editor invited
On 16 Mar, 2021
Review #? received
Received 16 Mar, 2021
First submitted
On 11 Mar, 2021
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Purpose: To assess the prognostic effect of different levels of IKZF1 gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
Methods: IKZF1 Δ2-8/ALB deletions were quantified using multiplex real-time quantitative PCR in newly diagnosed pediatric BCP-ALL patients. Seventy-four patients with IKZF1 deletions ≥ 0.01% were included. Clinical characteristics, laboratory data, and treatment outcomes were analysed.
Results: The patients were divided into two groups: IKZF1 deletions < 1% (group A) and ≥ 1% (group B). Group B patients had a higher BCR-ABL1 positive rate than did group A patients. The proportions of patients who had an age at onset ≥10 years old, and white blood cell count ≥ 50×109/L were significantly higher in group B than in group A. The 3-year overall survival (OS) and 3-year event-free survival (EFS) rates in group B were 79 ± 8.8% and 62.4 ± 9.7%, respectively, being significantly lower than those in group A (97.7 ± 2.2% and 83.2 ± 5.8%, respectively). The level of IKZF1 deletions ≥ 1% and the central nervous system leukemia were independent risk factors of EFS.
Conclusions: Pediatric BCP-ALL patients with high levels of IKZF1 gene deletions have a poorer prognosis than those with low levels.
Figure 1
Figure 2
Figure 3
Loading...